Details of the Drug

General Information of Drug (ID: DM5DWMU)

Drug Name

Rimantadine

Synonyms

Remantadine; Riamantadine; Rimant; Rimantadina; Rimantadinum; Enamine_005755; Alpha-Methyladamantanemethylamine; Flumadine (TN); Rimantadina [INN-Spanish]; Rimantadine (INN); Rimantadine [INN:BAN]; Rimantadinum [INN-Latin]; Alpha-Methyl-1-adamantanemethylamine; Rimant & .alpha. IFN; Rimantidine & .alpha.IFN; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-& IFN.alpha; 1-(1-Adamantyl)ethanamine; 1-(1-Adamantyl)ethylamin; 1-(1-adamantyl)-ethylamine; 1-(1-adamantyl)ethylamine; 1-(adamantan-1-yl)ethan-1-amine; 1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine; 1-Adamantan-1-yl-ethylamine; 1-Adamantan-1-ylethylamine; 1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine

Indication

Disease Entry	ICD 11	Status	REF
Influenza A virus infection	1E30	Approved	[1]

Therapeutic Class

Antiviral Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

179.3

Topological Polar Surface Area (xlogp)

2.6

Rotatable Bond Count (rotbonds)

1

Hydrogen Bond Donor Count (hbonddonor)

1

Hydrogen Bond Acceptor Count (hbondacc)

1

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Elimination: 20% of drug is excreted from urine in the unchanged form [2]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.934 micromolar/kg/day [3]
Water Solubility: The ability of drug to dissolve in water is measured as 50 mg/mL [2]

Chemical Identifiers

Formula: C12H21N
IUPAC Name: 1-(1-adamantyl)ethanamine
Canonical SMILES: CC(C12CC3CC(C1)CC(C3)C2)N
InChI: InChI=1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3
InChIKey: UBCHPRBFMUDMNC-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5071
ChEBI ID: CHEBI:94440
CAS Number: 13392-28-4
DrugBank ID: DB00478
TTD ID: D0TQ1G
VARIDT ID: DR00832
INTEDE ID: DR2305
ACDINA ID: D00596

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Influenza M2 protein (Influ M)	TTXT3PU	M2_I34A1	Inhibitor	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Rimantadine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Rimantadine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[9]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Rimantadine and Bupropion.	Nicotine use disorder [6C4A]	[10]
-----------

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sunset yellow FCF	E00255	17730	Colorant
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Rimantadine 100 mg tablet	100 mg	Oral Tablet	Oral
Rimantadine Hydrochloride 100mg tablet	100mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019649.
2	BDDCS applied to over 900 drugs
3	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4	Antiviral resistance of influenza A (H3N2) strains isolated in northern Greece between 2004 and 2007. Euro Surveill. 2009 Jan 29;14(4). pii: 19104.
5	Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc. 2009 Jun 17;131(23):8066-76.
6	Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A. 2010 July 13; 107(28): 12658-12663.
7	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
9	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
10	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.